Lymphocyte Replication in Lung Cancer Patients Undergoing Radiotherapy

Prasad, Nagendra; Prasad, Rajendra; Ji, Thornby; Harrell, James E.; Hudgins, Philip T.

doi:10.1159/000225415

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune and inflammation are critical for tumor progression, metastatic dissemination, and treatment resistance (8). Absolute lymphocyte count (ALC), plateletto-lymphocyte ratio (P/L ratio), neutrophil-to-lymphocyte ratio (N/L ratio), and lymphocyte-to-monocyte ratio (L/M ratio) were related to survival outcomes in various cancers (9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation

Yu¹,

Wang²,

Cao³

et al. 2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Few small sample size studies have reported lymphocyte count was prognostic for survival in small-cell lung cancer (SCLC). This study aimed to validate this finding, to build prediction model for overall survival (OS) and to study whether novel models that combine lymphocyte-related variables can predict OS more accurately than a conventional model using clinical factors alone in a large cohort of limited-stage SCLC patients.Methods: This study enrolled 544 limited-stage SCLC patients receiving definitive chemo-radiation with pre-radiotherapy lymphocyte-related variables including absolute lymphocyte count (ALC), platelet-tolymphocyte ratio (P/L ratio), neutrophil-to-lymphocyte ratio (N/L ratio), and lymphocyte-to-monocyte ratio (L/M ratio). The primary endpoint was OS. These patients were randomly divided into a training dataset (n=274) and a validation dataset (n=270). Multivariate survival models were built in the training dataset, and the performance of these models were further tested in the validation dataset using the concordance index (C-index).Results: The median follow-up time was 36 months for all patients. In the training dataset, univariate analysis showed that ALC (P=0.

show abstract

Section: Introductionmentioning

confidence: 99%

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation

Yu¹,

Wang²,

Cao³

et al. 2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

Lymphatisches System

Renner¹

1985

Handbuch Der Medizinischen Radiologie / Encyclopedia of Medical Radiology

View full text Add to dashboard Cite

Effects of Glutamine Supplements and Radiochemotherapy on Systemic Immune and Gut Barrier Function in Patients With Advanced Esophageal Cancer

Yoshida¹,

Matsui²,

Shirouzu³

et al. 1998

Annals of Surgery

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to determine whether oral glutamine supplements can protect lymphocyte and gut barrier function in patients with advanced esophageal cancer undergoing radiochemotherapy. Summary Background DataGlutamine supplements improved protein metabolism in tumor bearing rats who underwent chemotherapy and reduced the toxicity of chemotherapy through an enhancement of glutathione production in rats. MethodsThirteen patients with esophageal cancer were randomly placed in either a control or a glutamine group. Glutamine was administered orally (30 g/day) at the start of radiochemotherapy and for the subsequent 28 days. All patients underwent mediastinal irradiation and chemotherapy consisting of 5-fluorouracil and cisplatin. The lymphocyte count was determined, and blast formation was assessed after stimulation with phytohemagglutinin and concanavalin A. Gut barrier function was assessed by measuring the total amount of phenolsulfonphthalein excreted in the urine after the oral administration of phenolsulfonphthalein. ResultsGlutamine supplements prevented a reduction in the lymphocyte count (control: 567 ± 96/mm3 vs. glutamine: 1007 + 151, p < 0.05), and blast formation of lymphocyte (phytohemagglutinin, control: 19478 ± 2121

show abstract

Lymphocyte Replication in Lung Cancer Patients Undergoing Radiotherapy

Cited by 3 publications

References 8 publications

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation

Lymphatisches System

Effects of Glutamine Supplements and Radiochemotherapy on Systemic Immune and Gut Barrier Function in Patients With Advanced Esophageal Cancer

Contact Info

Product

Resources

About